Compare AbbVie Inc (ABBV) vs Iris Energy Limited (IREN) Price & Performance

AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.

The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.

IREN stock trades at $43.91, up 13.11% today amid speculation about a potential $22 billion Anthropic deal. The technical picture remains bearish despite the rally, with the stock missing earnings expectations for three consecutive quarters. Revenue growth appears strong with 2026 projections showing $757 million, though profitability metrics show negative ROE and ROA. Analyst consensus remains bullish with a $79.11 price target despite recent volatility.

The investment case hinges on IREN's transition from Bitcoin mining to AI infrastructure, with significant capacity expansion funded by substantial financing activities. Key risks include execution challenges in scaling operations, competitive pressure from established cloud providers, and reliance on speculative contract wins. The current valuation at 57x P/E appears stretched given negative returns on equity.